Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CStone Pharmaceuticals ( (HK:2616) ) has shared an announcement.
CStone Pharmaceuticals announced its participation in the 2025 European Society for Medical Oncology Congress, where it will present data from its ongoing clinical trials. The company will showcase the world’s first clinical data for a PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, in advanced solid tumor patients, and provide an update on the ROR1-targeting ADC, CS5001. These presentations highlight CStone’s commitment to advancing innovative cancer therapies and may enhance its positioning in the biopharmaceutical industry.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
More about CStone Pharmaceuticals
CStone Pharmaceuticals, established in 2015 and listed on the Hong Kong Stock Exchange, is an innovation-driven biopharmaceutical company focused on oncology, autoimmune/inflammation, and other key disease areas. The company has launched four innovative drugs and secured approvals for 16 new drug applications across nine indications. Its pipeline includes promising candidates like antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines.
Average Trading Volume: 23,139,181
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.88B
See more data about 2616 stock on TipRanks’ Stock Analysis page.